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Received July 3, 2012; accepted November 9, 2012AbstractAn umbrella concept addressing the relationship between chronic kidney disease (CKD) and mineral and bone disorders has been developed
in recent years. Given the high prevalence of osteoporosis-related fractures in postmenopausal women with CKD, especially those undergoing
chronic hemodialysis, the strategy used in the prevention and management of CKD and its associated osteoporosis in these postmenopausal
women has become a topic of substantial debate. This controversy has ongoing relevance because osteoporosis results in a significant economic
burden secondary to increased morbidity and mortality. The perfect goal of treatment and prevention includes both bone protection and renal
protection, or at least protection of one disease without compromising the other disease. Both CKD and osteoporosis are frequently observed in
the same patients, and often have parallel progression in postmenopausal women. Estrogen, the main female hormone during reproductive age,
has been reported to have a protective effect on kidney fibrosis in several animal models, and is also considered one of the most effective drugs in
the management of postmenopausal women with osteoporosis and prevention of osteoporosis. However, due to the many adverse events
associated with the use of estrogen with and without progestin, some of which have contributed to significant morbidity and mortality, drug
modification, which has had fewer reported incidences of adverse events without compromising the protective effect on both the kidney and
bone, may have an easier road to acceptance. Therapeutic alternatives, such as the selective estrogen receptor modulators (SERMs), have shown
the benefits of estrogen on bone, serum lipid levels, and renal protection, without any adverse effects on the breast and endometrium. The
Multiple Outcomes of Raloxifene Evaluation trial (MORE) and its extensiondContinuing Outcomes Relevant to Evista (CORE), a double-
blind, randomized clinical trial encompassing postmenopausal women with osteoporosis, showed promising results in both bone and renal
studies. Raloxifene increased bone mineral density (BMD) in the spine and femoral neck and reduced the risk of vertebral fracture. In addition,
raloxifene slowed the increase in the rate of serum creatinine and also significantly slowed the decrease in the estimated glomerular filtration
rate; of most importance, raloxifene use was associated with significantly fewer kidney-related adverse events. Hemodialyzed women on ral-
oxifene treatment demonstrated increased trabecular BMD, a decrease in bone resorption markers, and a decrease in the low-density lipoprotein-
cholesterol value. Thus, raloxifene and, most likely, other SERMs could be better in place of estrogen in the management of postmenopausal* Corresponding author. Dr. Peng-Hui Wang, Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road
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Osteoporosis is defined by a decrease in bone mass and an
alteration of microarchitecture, and a tendency toward subse-
quent fracture, which leads to debilitating health outcomes and
consequently a considerable economic burden on the health-
care system.1 In Taiwan, the incidence of vertebral fracture in
women older than 65 years is approximately 20%, and the
number of annual reported hip fractures in all populations age
65 years or older in Taiwan was 13,075 in 2002.2e4
There are many risk factors associated with osteoporosis,
including advancing age, lack of estrogen (caused by meno-
pause), vitamin D and/or calcium deficiency, low body weight
or low body mass index (BMI), immobility, current smoking,
excessive alcohol consumption, endocrine diseases, the use of
certain medications (such as glucocorticoids, gonadotropin-
releasing hormone agonists, or chemotherapy-induced early
menopause), surgical intervention, family history, and chronic
kidney disease (CKD).5e10 Among the aforementioned risk
factors, CKD is easily overlooked. In fact, an umbrella
concept addressing the relationship between CKD and mineral
bone disorders has been developed in recent years.11
CKD is defined as decreased renal function and/or renal
damage persisting for at least 3 months.11 Kidney dysfunction
is indicated by a glomerular filtration rate (GFR) less than
60 mL/min per 1.73 m2, and renal damage is most frequently
manifested as increased urinary albumin excretion (e.g., a
urinary albumin-creatinine ratio more than 30 g/g).11 CKD is
further classified into five stages: Stage 1 with GFR  90 mL/
min per 1.73 m2; Stage 2 with GFR of 60e89 mL/min per
1.73 m2; Stage 3 with GFR of 30e59 mL/min per 1.73 m2;
Stage 4 with GFR of 15e29 mL/min per 1.73 m2; Stage 5 with
GFR less than 15 mL/min per 1.73 m2.11 CKD is often sec-
ondary to many medical illnesses and also leads to debilitating
health outcomes, and consequently, a considerable economic
burden on the healthcare system because CKD not only ex-
acerbates the original precipitating diseasesddiabetes and
hypertension–and cardiovascular diseasesdmyocardial
infarction, stroke, and congestive heart failure, but also in-
duces many CKD-associated complications, such as end-stage
renal disease (ESRD), and chronic kidney disease-mineral and
bone disorders (CKD-MBD). CKD-MBD describes a broader
clinical syndrome that includes mineral disturbance and
abnormal metabolism of bone-regulating hormone, various
bone disorders, and calcification of soft tissues.11,12 In addi-
tion to renal osteodystrophy in patients with CKD, post-
menopausal women on hemodialysis are at high risk of
osteoporosis. In fact, both CKD and osteoporosis arefrequently observed in the same patients and have parallel
progress in postmenopausal women. Because estrogen defi-
ciency is a key cause of osteoporosis in postmenopausal
women, the role of estrogen and similar agents, such as se-
lective estrogen receptor modulators (SERMs),is worthy of
our attention,13 and there has been evidence that these com-
pounds might improve both CKD and osteoporosis in post-
menopausal women.14
2. Estrogen and bone
Due to the close relationship between estrogen deficiency
and osteoporosis, the use of estrogen therapy or its combination
with progestogen after menopause has been theoretically
reasonable.15 The use of estrogen in these postmenopausal
women significantly decreases the risk of osteoporosis and
subsequent fracture, as reported in a large double-blind ran-
domized clinical trial, the Women’s Health Initiative (WHI)
trial, in 2002.16 TheWHIwas the first large, randomized clinical
trial to show that estrogen-progestin therapy (EPT) reduces
osteoporotic fractures, including a 34% reduction in both
vertebral and hip fractures, and that this reduction occurred even
though the study patients were at low risk for fractures.16
However, a recent Cochrane database systematic review,
including 19 trials and 41,904 women, showed a significant
increase in the risk of venous thromboembolism or a coronary
event (after 1 year’s use), stroke (after 3 years’ use), and breast
cancer and gallbladder diseases in relatively healthy women
after continuous EPT, and an increase in all risks (thrombo-
embolism: after 1 to 2 years’ use; stroke: after 3 years’ use;
gallbladder disease: after 7 years’ use), except breast cancer
after estrogen-only treatment,17 which impeded the acceptance
of estrogen use in the prevention and management of post-
menopausal women with osteoporosis. Therefore, pure estro-
gens might not be a good choice in the management of
postmenopausal women with osteoporosis.
3. Estrogen and the kidney
The effect of estrogen on the kidney is uncertain.18 There
are at least three distinct estrogen receptors (ERs), including
ERa, ERb, and GPER (referred to as G-protein-couple protein
30) expressed in the kidney, although the distribution of the
individual ERs seemed to be different in renal tissue, sug-
gesting the potential role of estrogen in regulating renal
function.18 Estrogen can suppress collagen synthesis in
glomerular mesangial cells by attenuating angiotensin II-
induced mitogen-activated protein kinase activity and the
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inhibit proliferation of glomerular mesangial cells by modu-
lating the synthesis of growth promoters and growth inhibitors,
which might limit the progression of glomerulosclerosis,
because increased generation and deposition of extracellular
matrix proteins is considered as an initial step in glomerular
injury and loss of renal function.19 Various animal models of
renal diseases have shown that the progression of renal injury
is slower in female animals than in their male littermates, that
disease progression in male rats could be slowed by estrogen
substitution or orchiectomy, that estrogen application reduced
proteinuria and glomerular fibrosis after experimental renal
damage in different animal models, and that the expression of
glomerular damage markers, including desmin, in spontane-
ously hypertensive rats and rats after puromycin treatment
could be attenuated by estrogen treatment.20e23 In the ische-
miaereperfusion in vitro and in vivo models, estrogen also
reduced postischemic glomerular endothelial hyper-
permeability at least in part through receptor GPR30, and may
regulate postcardiac arrest and cardiopulmonary resuscitation
(CA/CPR) glomerular permeability in a similar fashion
in vivo.24
In addition to animal studies, epidemiologic studies also
supported the concept of renal protection with estrogen.25e27
The physiologic decline of renal function during aging is
significantly faster in healthy males than in females (loss of
glomerular filtration rate [GFR] of 8.7 mL/min/1.73 m2 per
decade in healthy male kidney donors compared to 1.4 mL/
min/1.73 m2 per decade in females, as measured by inulin
clearance).25 Two large meta-analyses investigating sex dif-
ferences in chronic renal disease or type I diabetes mellitus
showed a favorable renal outcome and a decreased risk for the
development of diabetic nephropathy in female patients
compared to their male counterparts.26,27 Taken together, ev-
idence supports the beneficial effect of estrogen on the kidney.
However, the relationship between estrogen therapy and renal
function in postmenopausal women is uncertain, because some
studies favored the relationship28 and some argued against it.29
Based on previous reports, the substitution of estrogen does
not provide a reasonable therapeutic option due to the sig-
nificant adverse effects30; SERMs or nonreceptor- mediated
estrogen metabolites may offer promising options for targeted
therapy for renal diseases.
4. Estrogen and estrogen receptors
Before discussing SERMs, a brief introduction to the
classic estrogen/ER pathway is needed. In this pathway, es-
trogen action at target sites around the body is mediated
through related but distinct ERa and ERb, which then bind as
dimers to estrogen-response elements in the regulatory regions
of the estrogen-responsive genes, and associate with basal
transcription factors, coactivators, and corepressors to alter
gene expression.13 However, recent evidence has indicated
that another pathway may exist.31 The presence of specific,
high-affinity estrogen binding in nonnuclear subcellular frac-
tions, including plasma membrane and mitochondria, impliesother sites of the ER location.31 ERa and ERb show 96%
amino-acid identity in their DNA-binding domains, but only
53% homology is noted in their ligand-binding domains; the
latter accounts for the differences in the responses of the two
receptors to various ligands. For example, tamoxifen (TAM,
Nolvadex; AstraZeneca, Wilmington, DE, USA) has been re-
ported to be both an agonist and an antagonist for ERa, but
only an antagonist for ERb.13 The recognition that TAM and
other SERMs, for example, raloxifene (Evista, Eli Lilly,
Indianapolis, IN, USA), have tissue-specific agonist-antago-
nist activity led to the realization that the classic model was
incomplete and that estrogen action was more complex than
had been thought.32 The mechanisms of the tissue-selective,
mixed agonist-antagonist action of SERMs, although still
only partly understood, are gradually becoming clearer.33
Most of the unique pharmacology of SERMs can be
explained by three interactive mechanisms: differential ER
expression in a given target tissue, differential ER conforma-
tion on ligand binding, and differential expression and binding
to the ER of coregulator proteins.334.1. The efficacy of raloxifene in women with bone
protectiondresults from three clinical trials (MORE,
CORE, and RUTH)There are three clinical trials addressing the influence of
raloxifene on bone health, even though the primary end points
of the individual trials were different.34e43 The first trial was
the MORE (Multiple Outcomes of Raloxifene Evaluation;
7705 postmenopausal women) study, which investigated the 4-
year effect of raloxifene on the skeleton (on the risk of
vertebral and nonvertebral fractures).34e40 The second trial
was an extension trial of the MOREd the CORE (Continuing
Outcomes Relevant to Evista; 4011 women continuing from
MORE, with a mean age of 65.8), which evaluated the efficacy
of an additional 4 years of raloxifene therapy in preventing
invasive breast cancer in women who participated in the
MORE trial.41 The third trial was the RUTH (Raloxifene Use
for The Heart; 10,101 postmenopausal women, mean age, 67.5
years), which was originally designed to determine the effect
of raloxifene on the incidence of coronary events (i.e., death
from coronary causes, nonfatal, including silent myocardial
infarction, or hospitalization for an acute coronary syndrome
other than myocardial infarction) and invasive breast cancer.43
The bone mineral density (BMD) gains after 3 years were
2.1% in the spine and 2.6% in the femur. Significant
concomitant decreases in osteocalcin (26.3% vs. 8.6% in
the placebo group) and urinary cross-linked N-telopeptides of
type I collagen (NTX) (34% vs. 8.1% in the placebo
group) were noted. BMD gains after 4 years were 2.6% in the
spine and 2.1% in the femur.34 After 7 years of treatment (4
years in MORE and 3 years in CORE), BMD was higher in the
raloxifene group than in the placebo group, by 2.2% in the
spine and 3% in the total hip ( p < 0.01).42
Raloxifene was efficacious (vertebral fracture reduction of
30% in women with and 55% in women without prevalent
fractures in 3 years, respectively),34 sustainable (a 50%reduction
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(68% reduction, p¼ 0.01, in a 1-year post hoc analysis, and 90%
reduction,p¼ 0.01, in a 6-monthpost hoc analysis),37,38 andvery
fast-acting (80% reduction, p ¼ 0.034, in a 3-month post hoc
analysis).38 The efficacious effect of raloxifene in decreasing
vertebral fracturewas also seen in the CORE study (170 fracture
events (20.4%)with the placebo compared to 121 fracture events
(14.1%) with raloxifene treatment).42 Consistent with MORE
and CORE trials, the RUTH trial clearly demonstrated the ben-
efits of raloxifene in the prevention of clinical vertebral fracture
(35% reduction, p ¼ 0.007).43
Raloxifene not only offers benefits in the absolute reduction
of the risk of vertebral fractures, but also ameliorates the
severity of future vertebral fracture.39 First, raloxifene can
decrease the severity of all vertebral fractures; the risk of at
least one new moderate/severe vertebral fracture was
decreased by 61% in women without prevalent vertebral
fractures (relative risk (RR) ¼ 0.39, 95% confidence interval
(CI) ¼ 0.17 w 0.69), and by 37% in women with prevalent
vertebral fractures (RR ¼ 0.63, 95% CI ¼ 0.49 w 0.83) at 3
years. Second, raloxifene also decreased the absolute number
of vertebral fractures. The cumulative relative risks of multiple
( 2) new vertebral fractures through 4 years were 0.54 (95%
CI ¼ 0.38w 0.77) with raloxifene compared with a placebo.40
However, these benefits of vertebral fracture prevention
seemed to be absent with nonvertebral fracture. The risk
reduction for nonvertebral fractures in the overall MORE pop-
ulation was not significant, although a reduction of 47%
( p ¼ 0.04) was noted in a post hoc analysis of patients with
severe (semiquantitative grade 3) prevalent vertebral frac-
tures.40 the risk reduction for nonvertebral fractures in the
overall CORE population was not significant.41 The risk of at
least one new nonvertebral fracture was similar in the placebo
(22.9%) and raloxifene (22.8%) groups (hazard ratio
[HR] ¼ 1.00; Bonferroni-adjusted CI ¼ 0.82w1.21).42 The
incidence of at least one new nonvertebral fracture at six major
sites (clavicle, humerus, wrist, pelvis, hip, lower leg) was 17.5%
in both groups. Post hoc Poisson analyses, which account for
multiple events, showed no overall effect on nonvertebral frac-
ture risk; however, a decreased risk (a reduction of 22%) was
found at six major nonvertebral sites in women with prevalent
vertebral fractures (HR ¼ 0.78; 95% CI ¼ 0.63 w 0.96,
p¼ 0.017) and with severe (baseline semiquantitative technique
(SQ) grade 3) vertebral fractures (HR ¼ 0.64; 95%
CI ¼ 0.44 w 0.92, p < 0.05).41 For hip fracture prevention,
raloxifene did not show any advantage (HR ¼ 1.04; 95%
CI ¼ 0.60 w 1.82).42 Consistent with the MORE and CORE
trials, the RUTH trial also showed that raloxifene was not suf-
ficient to prevent nonvertebral fractures, because there was no
difference in nonvertebral fractures between the raloxifene
treatment and placebo groups.43
5. The efficacy of raloxifene in women with bone
protection in Asian countries
The efficacy of raloxifene in osteoporosis prevention and
treatment has been proven not only in populations in Westerncountries (the United States and Europe), but also in Asian
countries.44,45 One study included 968 healthy postmenopausal
Asian women (mean age, 57 years) from Australia, Hong
Kong, India, Indonesia, Malaysia, Pakistan, Philippines,
Singapore, Taiwan, and Thailand. In comparison with a pla-
cebo, raloxifene significantly decreased osteocalcin and N-
telopeptide by medians of 15.9% and 14.6%, respectively, and
increased mean lumbar spine BMD (1.9%) at 1 year
( p ¼ 0.0003). In Japan, a similar result was noted.45 Compared
to baseline, women taking raloxifene had significant increases
in lumbar spine (L2-L4) BMD at 24 weeks (þ3.3%, p < 0.001)
through 52 weeks (þ3.5%, p < 0.001) of therapy.455.1. In vitro and in vivo models of renal protection with
SERM treatmentAs mentioned previously, accumulation of glomerular
extracellular matrix after renal injury is a precursor to the
development of glomerular obsolescence and progressive loss
of renal function. A study on the inhibition of collagen syn-
thesis or mesangial cell proliferation can be presented as a
model to evaluate the effect of SERMs on renal function.
SERMs, including tamoxifen and raloxifene, were reported to
suppress COL4A1 gene transcription (fibrogenic cytokines)
and type IV collagen protein synthesis in a dose-dependent
manner, with a potency identical to that of estradiol, and
type I collagen synthesis was also suppressed by raloxifene in
a dose-dependent manner, with a potency identical to that of
estradiol, but greater than that of tamoxifen.46 Tamoxifen
prevented the accumulation of extracellular matrix by
decreasing the expression of collagen III and fibronectin
messenger RNA and protein, with a significant reduction in a-
smooth muscle active-positive cells in the renal interstitium.47
SERMs also reversed the stimulatory effects of angiotensin II
and endothelin-1 on COL4A1 gene transcription and type IV
collagen synthesis via antagonisms of the autocrine/paracrine
effects of transforming growth factor-b1 (TGF-b1).47 In our
previous study, we also found that raloxifene could induce
apoptosis of fibroblast (for renal scar formation) via the G
protein and PI3K/Akt pathways,48,49 suggesting that prolifer-
ation of the fibroblast was inhibited by raloxifene, which
might be associated with a lower degree of tissue scarring.
In an investigation of the vascular effect of raloxifene on
isolated rat intralobar renal arteries, with and without a
functional endothelium, raloxifene-induced renovascular
relaxation was independent of the presence of the endothelium
or ICI-182, 780-sensitive ERs (Sigma, St. Louis, MO, USA).
This effect was approximately fivefold more effective than
estradiol and was unrelated to ERs.50 In addition, raloxifene
reduced CaCl2-mediated contraction and inhibited Ca
2þ
influx, which might be through L-type Ca2þ channels.50
In a study of the effect of SERMs on ameliorating renal
damage in db/db mice, raloxifene suppressed TGF-
b1einduced fibronectin promoter activity and AP-1 activation
in cultured mesangial cells, suggesting that raloxifene has a
beneficial effect on the kidney in vivo and may be more useful
than estrogen as a clinical therapy for diabetic nephropathy.51
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nity for renal protection in in vitro and in vivo studies.
6. Clinical studies showed the benefits of SERM treatment
in renal protection
In the post hoc analysis of a MORE trial,52 serum creatinine
increased by 0.004 mg/dL per year on average ( p < 0.0001),
with women on raloxifene 60 mg showing a slower rate of
increase over time than those women in the placebo group.
The 3-year mean increase of serum creatinine was 0.01 mg/dL
in the placebo group, but 0.0004 mg/dL with raloxifene
treatment.52 The 3-year mean decrease of the estimated GFR
was 0.98 mL/min per 1.73 m2 in the placebo group, but
0.56 mL/min per 1.73 m2 in the raloxifene group, with women
on raloxifene decreasing at a slower rate over time than those
women in the placebo group ( p ¼ 0.03).52 In addition, 28
women (0.6%) in the raloxifene group and 29 women (1.1%)
in the placebo group had an adverse event related to kidney
function, with a relative HR of 0.37 (95%
CI ¼ 0.18 w 0.77).51 The risk of incident events related to
kidney disease among those with probable kidney disease at
baseline was also reduced by treatment with raloxifene (rela-
tive HR 0.27 (95% CI ¼ 0.12w0.59).52 Therefore, raloxifene
showed a renoprotective effect in postmenopausal women.
7. Clinical studies showed the benefits of SERM treatment
in postmenopausal women with CKD
A small, prospective, blinded, placebo-controlled, and
randomized study that enrolled 50 postmenopausal women on
chronic hemodialysis showed a significant decrease in the
LDL-cholesterol value, suggesting that raloxifene might con-
trol hyperlipidemia and provide a favorable lipid profile for
these postmenopausal women on chronic hemodialysis.53 In
addition, raloxifene lowered serum malondialdehyde and ni-
tric oxide and decreased the LDL serum level, but increased
HDL serum levels in postmenopausal women who were un-
dergoing long-term hemodialysis treatment for chronic renal
failure.54
8. Clinical studies showed the benefits of SERMs on bone
health in postmenopausal women with CKD
A significant increase in trabecular BMD and a decrease in
bone resorption markers (pyridinoline crosslinks) suggest that
raloxifene constitutes a therapeutic alternative for the improve-
ment of bone metabolism in these postmenopausal women on
chronic hemodialysis.53 However, many factors might affect the
efficacy of raloxifene in bone health in postmenopausal women
with CKD. For example, the ER gene polymorphism may affect
the efficacy of raloxifene in increasing BMD in postmenopausal
women on chronic hemodialysis.55 The level of intact para-
thyroid hormone is also reported to affect the efficacy of ralox-
ifene in the prevention of BMD deterioration in postmenopausal
patients undergoing dialysis.56 One study showed that raloxifene
significantly decreased serum calcium and increased intactparathyroid hormone in postmenopausal Japanese women on
hemodialysis, suggesting that vitamin D and/or calcium salts
should be added to raloxifene treatment to avoid secondary
hyperparathyroidism.14
9. The potential risk of raloxifene in women
The potential risk of raloxifene treatment is thromboem-
bolism. A meta-analysis evaluating the effect of raloxifene on
the risk of deep vein thrombosis (DVT) and pulmonary em-
bolism (PE) showed that therapy with raloxifene was associ-
ated with a 62% increase in the odds of either DVT or PE
(odds ratio (OR) ¼ 1.62; 95% CI ¼ 1.25 w 2.09;
p < 0.001).57 Raloxifene therapy was associated with a 54%
increase in the odds of DVT (OR ¼ 1.54; 95%
CI ¼ 1.13w 2.11; p ¼ 0.006) and a 91% increase in the odds
of PE alone (OR ¼ 1.91; 95% CI ¼ 1.05w 3.47; p ¼ 0.03),57
although it was probably not associated with an increased risk
of arterial thromboembolism.58 Raloxifene might improve
platelet metabolism in healthy postmenopausal women
through an increase of the bioavailability of platelet nitric
oxide by a reduction of inducible nitric oxide synthase and the
beneficial effects on lipid metabolism.59 However, other
adverse effects, such as the higher frequency of hot flushes,
cramps of the lower limbs, and fluid retention may be a reason
for halting raloxifene use in menopausal women.60
10. Unanswered questions
Because the spectrum of chronic kidney disease-mineral and
bone disorders is widely ranged, the following factors come into
play: (1) some have severe high-turnover bone disease and the
others have marked low bone turnover bone disease; (2) some
have severe vascular calcificationswhereas others do not; (3) the
values of biochemistry determinations, including calcium,
phosphorus, and parathyroid hormone vary widely among pa-
tients; (4) the variability may be influenced by the chronicity of
the particular kidney disease, effects of therapies such as cor-
ticosteroids on modifying the course of kidney disease, and
comorbid condition, there is no doubt that it is difficult to make
strict protocol-driven therapeutic approaches in the manage-
ment of these patients with CKD due to heterogeneities.61 In
addition, there is a good correlation between dual-energy X-ray
absorptiometry measurements and bone fractures in the general
population, but this is not the case with patients with CKD,62
especially in the Stage 5 CKD population, which results in a
lack of consensus on the diagnosis of osteoporosis in Stage 5
CKD patients.63 Furthermore, although some of the small
aforementioned trials suggested the potential benefits of SERMs
on bone health in postmenopausal dialysis patients,53,55,56 the
benefits of SERMs might vary among the different stages of
CKD. Finally, although post hoc analyses of many pivot trials
(bisphosphonates, raloxifene, teriparatide, denosumab) have
found similar results (benefits of the aforementioned drugs on
bone health) in thosewith andwithout mild CKD, it is important
to remember that patients with abnormal laboratory values were
often excluded from these trials.64 Therefore, it is relatively
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medications) for those Stage 5 CKD patients with osteoporosis.
By contrast, before consensus formed, considerable individu-
alized or patient-tailored therapy is recommended, especially
for those women with Stage 5 CKD and osteoporosis.61
In conclusion, these observations (MORE, CORE, RUTH
trials) have shown the efficacy of raloxifene in terms of the pre-
vention and management of osteoporosis, decreased bone turn-
over, increased BMD, and decreased incidence of fracture, as
well as the slower yearly rate of increase in creatinine, signifi-
cantly slower yearly rate of decreases in estimated GFR, and
significantly fewer kidney-related adverse events. Furthermore,
Asian populations do have a low risk of thromboembolism,65 but
a high percentage of these populations have gastrointestinal tract
problems66; therefore, it is reasonable to use raloxifene in Asian
postmenopausal women with CKD and osteoporosis. Raloxifene
offers the best benefits for a specific population–climacteric
symptom-free postmenopausalwomen, especiallyAsianwomen,
who need renal protection and have CKD-MBD, although more
evidence is required to support this recommendation.
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